| 11141489 |
Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid |
Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart +5 more |
2021-10-12 |
$18,446,000 |
| 11046743 |
Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes |
Torsten Haack, Oliver Plettenburg, Michael Wagner, Martin Bossart, Romain BERTRAND |
2021-06-29 |
|
| 10806797 |
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate |
Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Pradeep K. Dhal +7 more |
2020-10-20 |
$20,781,000 |
| 10792367 |
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid |
Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart +5 more |
2020-10-06 |
$12,700,000 |
| 10758592 |
Exendin-4 derivatives as dual GLP1/glucagon agonists |
Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Martin Bossart |
2020-09-01 |
$13,326,000 |
| 10583174 |
FGF21 compound / GLP-1R agonist combinations with optimized activity ratio |
Britta GÖBEL, Mark Sommerfeld, Oliver BOSCHEINEN, Thomas LANGER, Christine RUDOLPH |
2020-03-10 |
$11,366,000 |
| 10538567 |
Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists |
Martin Bossart, Torsten Haack, Dieter Kadereit, Katrin Lorenz, Michael Wagner +2 more |
2020-01-21 |
$21,956,000 |
| 10519211 |
Compounds as peptidic GLP1/glucagon/GIP receptor agonists |
Martin Bossart, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner +2 more |
2019-12-31 |
$5,348,000 |
| 10253079 |
Functionalized Exendin-4 derivatives |
Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Martin Lorenz +1 more |
2019-04-09 |
$12,447,000 |
| 9982029 |
Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
Martin Bossart, Torsten Haack, Katrin Lorenz, Dieter Kadereit, Michael Wagner +1 more |
2018-05-29 |
$11,844,000 |
| 9932381 |
Exendin-4 derivatives as selective glucagon receptor agonists |
Torsten Haack, Siegfried Stengelin, Michael Wagner, Bernd Henkel |
2018-04-03 |
$18,243,000 |
| 9834527 |
Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals |
Christopher Kallus, Michael Wagner, Hermut Wehlan |
2017-12-05 |
$11,040,000 |
| 9789165 |
Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists |
Dieter Kadereit, Katrin Lorenz, Torsten Haack, Michael Wagner, Bernd Henkel +2 more |
2017-10-17 |
$7,245,000 |
| 9775904 |
Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
Martin Bossart, Ralf Elvert, Torsten Haack, Siegfried Stengelin, Michael Wagner |
2017-10-03 |
$8,333,000 |
| 9771406 |
Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4 |
Martin Bossart, Ralf Elvert, Torsten Haack, Siegfried Stengelin, Michael Wagner +1 more |
2017-09-26 |
$18,404,000 |
| 9758561 |
Dual GLP-1/glucagon receptor agonists derived from exendin-4 |
Martin Bossart, Ralf Elvert, Torsten Haack, Siegfried Stengelin, Michael Wagner +1 more |
2017-09-12 |
$14,166,000 |
| 9751926 |
Dual GLP-1/GIP receptor agonists |
Dieter Kadereit, Katrin Lorenz, Torsten Haack, Michael Wagner, Bernd Henkel +2 more |
2017-09-05 |
$7,330,000 |
| 9750788 |
Non-acylated exendin-4 peptide analogues |
Dieter Kadereit, Katrin Lorenz, Torsten Haack, Michael Wagner, Bernd Henkel +2 more |
2017-09-05 |
$7,330,000 |
| 9745360 |
Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists |
Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Martin Lorenz +1 more |
2017-08-29 |
$18,132,000 |
| 9694053 |
Dual GLP-1/glucagon receptor agonists |
Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Martin Bossart +1 more |
2017-07-04 |
|
| 9688645 |
Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa |
Christopher Kallus, Mark Broenstrup, Anja Globisch, Herman Schreuder, Michael Wagner |
2017-06-27 |
$8,363,000 |
| 9670261 |
Functionalized exendin-4 derivatives |
Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Martin Lorenz +1 more |
2017-06-06 |
$14,464,000 |
| 9365632 |
Exendin-4 derivatives as dual GLP1/glucagon agonists |
Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Martin Bossart |
2016-06-14 |
$5,305,000 |
| 9346757 |
Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation |
Marc Nazare, Detlef Kozian, Werngard Czechtizky |
2016-05-24 |
$4,497,000 |
| 9346762 |
Pyrazole derivatives and their use as LPAR5 antagonists |
Marc Nazare, Detlef Kozian, Werngard Czechtizky |
2016-05-24 |
$4,497,000 |